American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer

Ethan M. Basch, Mark R. Somerfield, Tomasz M. Beer, Michael A Carducci, Celestia S. Higano, Maha H A Hussain, Howard I. Scher

Research output: Contribution to journalReview article

Abstract

Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)5313-5318
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number33
DOIs
StatePublished - Nov 20 2007

Fingerprint

Castration
Ontario
Practice Guidelines
Prostatic Neoplasms
Hormones
Guidelines
docetaxel
Medical Oncology
Neoplasms
Therapeutics
Estramustine
Drug Therapy
Androgen Antagonists
Mitoxantrone
Radiopharmaceuticals
Cytotoxins
Diphosphonates
Prednisone
Androgens
Hydrocortisone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer. / Basch, Ethan M.; Somerfield, Mark R.; Beer, Tomasz M.; Carducci, Michael A; Higano, Celestia S.; Hussain, Maha H A; Scher, Howard I.

In: Journal of Clinical Oncology, Vol. 25, No. 33, 20.11.2007, p. 5313-5318.

Research output: Contribution to journalReview article

@article{9fc4bbe96fa54d04a4fc414488b3edbd,
title = "American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer",
abstract = "Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.",
author = "Basch, {Ethan M.} and Somerfield, {Mark R.} and Beer, {Tomasz M.} and Carducci, {Michael A} and Higano, {Celestia S.} and Hussain, {Maha H A} and Scher, {Howard I.}",
year = "2007",
month = "11",
day = "20",
doi = "10.1200/JCO.2007.13.4536",
language = "English (US)",
volume = "25",
pages = "5313--5318",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "33",

}

TY - JOUR

T1 - American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice Guideline on Nonhormonal Therapy for Men with Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer

AU - Basch, Ethan M.

AU - Somerfield, Mark R.

AU - Beer, Tomasz M.

AU - Carducci, Michael A

AU - Higano, Celestia S.

AU - Hussain, Maha H A

AU - Scher, Howard I.

PY - 2007/11/20

Y1 - 2007/11/20

N2 - Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

AB - Purpose: In 2006, the American Society of Clinical Oncology (ASCO) Board of Directors (BOD) approved a policy and a set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods: The Cancer Care Ontario (CCO) Guideline on Non-Hormonal Therapy for Men With Metastatic Hormone-Refractory Prostate Cancer (HRPC) was reviewed for developmental rigor by methodologists. An ad hoc prostate cancer guideline review panel consisting of prostate cancer experts reviewed the content. Results: The ASCO ad hoc prostate cancer guideline review panel concurred that the recommendations are clear, thorough, based on the most relevant scientific evidence in this content area, and present options that will be acceptable to patients. The CCO guideline was subsequently endorsed by the ASCO BOD. The guideline recommends the use of docetaxel, prednisone/ hydrocortisone, and/or mitoxantrone in specific settings. Docetaxel-based chemotherapy is the only treatment that has demonstrated an overall survival benefit in men with HRPC. The use of estramustine in combination with other cytotoxic agents is not recommended. Continued gonadal androgen suppression and discontinuance of antiandrogens is recommended for men receiving chemotherapy. Conclusion: The review panel agreed with the recommendations as stated in the CCO guideline, with the following qualifications: two of the ASCO content reviewers noted the importance of considering other, nonhormonal therapies in this context that are beyond the scope of this guideline. The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=36849038314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849038314&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.13.4536

DO - 10.1200/JCO.2007.13.4536

M3 - Review article

C2 - 17925542

AN - SCOPUS:36849038314

VL - 25

SP - 5313

EP - 5318

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 33

ER -